Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dura To Recruit 60 Reps For Glaxo Derm Line; Four Products Are Off-Patent

Executive Summary

Dura will promote Glaxo's dermatology product line through the establishment of a 60-sales rep dermatology sales force, the company said in an Oct. 2 conference call.

You may also be interested in...



Solaraze U.S. Autumn Launch Likely After Bioglan Purchase From SkyePharma

Bioglan Pharma is projecting an August/September launch in North America for its actinic keratoses product Solaraze (diclofenac gel, 3%) following a licensing agreement with SkyePharma.

Solaraze U.S. Autumn Launch Likely After Bioglan Purchase From SkyePharma

Bioglan Pharma is projecting an August/September launch in North America for its actinic keratoses product Solaraze (diclofenac gel, 3%) following a licensing agreement with SkyePharma.

Elan Inhales Spiros; Dura Buy Brings Marketing, Mature Products As Well

Elan is taking over the Spiros dry powder inhaler project six years after making a major alliance investment in the technology.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel